. 2023 Feb 14;209:107155. doi: 10.1016/j.rmed.2023.107155

Table 2.

Plasma levels of Cardiovascular Disese Risk Markers.

Conc. (ng/ml)	BC	C	BH	H	P
sVCAM	901.0 ± 166.2 (701.1–123.0)	937.5 ± 167.3 (732.1–1216.0)	960.2 ± 135.7 (718.9–1140.0)	877.2 ± 248.7 (525.3–1238.0)	0.0216 (#)
sPselectin	138.0 ± 25.8 (103.8–195.7)	143.8 ± 26.2 (101.9–181.7)	142.7 ± 23.7 (101.9–176.4)	136.5 ± 35.7 (76.5–192.0)	Ns
sICAM	177.8 ± 51.30 (116.2–259.8)	195.5 ± 59.46 (118.8–332,5)	192.1 ± 55.21 (122.2–272.1)	203.8 ± 54.24 (96.0–265.9)	Ns
SAA	16816 ± 3598 (11345–26353)	19974 ± 4336 (12043–28487)	17618 ± 3926 (11575–24874)	15487 ± 5362 (8281–23329)	0.0357 (#)
SAA	16816 ± 3598 (11345–26353)	19974 ± 4336 (12043–28487)	17618 ± 3926 (11575–24874)	15487 ± 5362 (8281–23329)	0.0097 (##)
MPO	57.41 ± 8.54 (42.10–79.60)	59.49 ± 5.88 (50.60–71.10)	58.60 ± 6.16 (44.20–65.80)	60.44 ± 11.41 (37.80–81.00)	Ns

Data are described as: mean ± SD (minimum-maximum). Abbreviations: BC: baseline control group, C: control group at t = 5 days, BH: baseline HBOT group, H: HBOT group at t = 5 days (n = 22–25 per group). P values for each analyte are listed and derive from paired t tests (H vs BH:#; C vs BC: ##). Significant differences are highlighted. Rest comparisons are ns.